论文部分内容阅读
目的探讨微生态制剂金双歧(双歧杆菌乳酸杆菌三联活菌片)对新生儿高胆红素血症的临床疗效,以找出能及早有效地纠正新生儿高胆红素血症,预防新生儿胆红素脑病发生的新方法。方法通过随机抽样、收集青白江区人民医院2007年3月至2011年3月72例新生儿高胆红素血症患儿的临床资料并进行回顾性分析,将72例新生儿高胆红素血症患儿随机分为治疗组40例和对照组32例。对照组给予常规治疗,治疗组在常规治疗基础上,加用金双歧1片(0.5亿)/次,每天3次,温开水溶碎后喂服或经胃管注入,共7～10 d。检测治疗前后两组血清胆红素水平、计算日平均经皮测胆红素下降值、平均住院时间和黄疸消退时间。结果金双歧辅助治疗新生儿高胆红素血症,治疗后治疗组与对照组血清总胆红素水平分别为(58.21±4.36)μmol/L和(64.16±5.29)μmol/L(P<0.01);治疗组和对照组日平均经皮测胆红素下降值、平均住院时间和黄疸退尽平均时间分别为(10.35±2.46)、(7.68±1.35)μmol/L;(6/54±2/59)、(9/05±3/12)d;(6/38±1/38)、(8/75±2/68)d;差异均有统计学意义(P<0.01)。结论应用金双歧治疗新生儿高胆红素血症可迅速降低血胆红素水平,缩短治疗时间,预防胆红素脑病的发生疗效确切、安全,可作为治疗新生儿高胆红素血症的方法之一,值得临床应用推广。
Objective To investigate the clinical efficacy of the probiotic Jin bifidobacterium (Lactobacillus bifidum triplex) on neonatal hyperbilirubinemia, so as to find out the effective and effective measures to correct neonatal hyperbilirubinemia effectively and prevent neonatal New method of bilirubin encephalopathy. Methods The clinical data of 72 neonates with hyperbilirubinemia from March 2007 to March 2011 in Qingbaijiang District People’s Hospital were collected and analyzed retrospectively by random sampling. Seventy-two neonates with hyperbilirubinemia Children with schizophrenia were randomly divided into treatment group 40 cases and control group 32 cases. The patients in the control group were given routine treatment. The patients in the treatment group were given Jinjianqi 1 tablet (0.5 billion) once daily for 7 to 10 days after they were dissolved in warm water and dissolved in warm water. The levels of serum bilirubin in the two groups before and after treatment were measured. The daily mean percutaneous bilirubin, the average length of stay, and the regression time of jaundice were calculated. Results Jinshuangqi adjuvant treatment of neonatal hyperbilirubinemia, serum total bilirubin levels of the treatment group and the control group were (58.21 ± 4.36) μmol / L and (64.16 ± 5.29) μmol / L, respectively ; The average daily mean percutaneous bilirubin drop, average length of stay and jaundice in treatment group and control group were (10.35 ± 2.46), (7.68 ± 1.35) μmol / L, (6/54 ± 2 / (9/05 ± 3/12) d, (6/38 ± 1/38) and (8/75 ± 2/68) d, respectively. The differences were statistically significant (P <0.01). Conclusion The treatment of neonatal hyperbilirubinemia with bifidobacterium can rapidly decrease the level of serum bilirubin, shorten the treatment time and prevent the occurrence of bilirubin encephalopathy. The curative effect is safe and can be used as a method to treat neonatal hyperbilirubinemia One, it is worth promoting clinical application.